Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single-Arm, Multicenter Clinical Study of Iparomlimab and Tuvonralimab in Combination With Paclitaxel Plus Cisplatin/Carboplatin and Radiotherapy for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

NCT06942416 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT06942416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06942416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single-Arm, Multicenter Clinical Study of Iparomlimab and Tuvonralimab in Combination With Paclitaxel Plus Cisplatin/Carboplatin and Radiotherapy for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 2
Overall status
Recruiting
Start date
February 28, 2025
Completion date
December 31, 2028
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, neoplasm recurrence, local, oligometastatic